Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 24Neoplasms 11Carcinoma, Non-Small-Cell Lung 9Prostatic Neoplasms 8Multiple Myeloma 8Lung Neoplasms 6Melanoma 5Leukemia, Myeloid, Acute 5Neoplasm Metastasis 4Glioma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Tuberous Sclerosis 3Stomach Neoplasms 3Sarcoma 3Papillomavirus Infections 3Leiomyoma 3Hematologic Neoplasms 3Glioblastoma 3Carcinoma, Renal Cell 3Polycythemia Vera 2Pain 2Oligodendroglioma 2Neoplasms by Site 2Myasthenia Gravis 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Heart Failure 2Febrile Neutropenia 2Endometrial Neoplasms 2Bronchiolitis Obliterans Syndrome 2

Interventions

ruxolitinib 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Thalassemia × 90 days × Clear all
NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Novartis

Phase 4 Active not recruiting
279 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡